Biosimilars, a deflationary pull against the upward push of inflation

Biosimilars generally enter the market priced at roughly 50% of the amount of their reference drugs.

With eight new biosimilars approved by midpoint 2024, these lower-cost biologics are one of the few deflationary factors in an otherwise relentlessly upward trend of medical cost inflation.